Cargando…

A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor

Detalles Bibliográficos
Autores principales:	Koike, Yuta, Murayama, Naoya, Kuwatsuka, Yutaka, Utani, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635246/ https://www.ncbi.nlm.nih.gov/pubmed/29034299 http://dx.doi.org/10.1016/j.jdcr.2017.06.028

Ejemplares similares

Calcification in dermal fibroblasts from a patient with GGCX syndrome accompanied by upregulation of osteogenic molecules
por: Okubo, Yumi, et al.
Publicado: (2017)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
por: Veale, Douglas J, et al.
Publicado: (2019)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
por: Qi, Fei, et al.
Publicado: (2021)

Janus kinase inhibitors: jackpot or potluck?
por: Pavithran, Keechilat, et al.
Publicado: (2012)

Janus Kinase Inhibitors and Cell Therapy
por: Assal, Amer, et al.
Publicado: (2021)

Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors
por: Garrido-Trigo, Alba, et al.
Publicado: (2020)

Role of janus kinase inhibitors in the treatment of alopecia areata
por: Triyangkulsri, Korn, et al.
Publicado: (2018)

Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib
por: Aboul-Fettouh, Nader, et al.
Publicado: (2018)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
por: Chen, Miao, et al.
Publicado: (2020)

Fibroblast growth factor 2 accelerates the epithelial–mesenchymal transition in keratinocytes during wound healing process
por: Koike, Yuta, et al.
Publicado: (2020)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis
por: Słuczanowska-Głąbowska, Sylwia, et al.
Publicado: (2021)

Janus kinase inhibitors in autoimmune bullous diseases
por: Huang, Dawei, et al.
Publicado: (2023)

Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors
por: Koike, Yuta, et al.
Publicado: (2020)

Attenuation of an adult T-cell leukemia skin lesion after treatment of a concomitant herpes simplex infection: a case study
por: Tomita, Hajime, et al.
Publicado: (2012)

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
por: Singh, Rhea, et al.
Publicado: (2020)

The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
por: Kim, Jin-Woo, et al.
Publicado: (2021)

A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
por: Tanaka, Yoshiya
Publicado: (2023)

Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis
por: Paroli, Marino, et al.
Publicado: (2023)

Response of Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Xenografts to a Survivin Inhibitor
por: Dresang, Lindsay R., et al.
Publicado: (2013)

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors
por: Knight, Emily A., et al.
Publicado: (2015)

The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: De Vries, L.C.S., et al.
Publicado: (2017)

Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
por: Nash, David, et al.
Publicado: (2022)

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
por: Núñez, Paulina, et al.
Publicado: (2023)

Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases
por: Haan, Claude, et al.
Publicado: (2010)

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
por: Singer, Jack W, et al.
Publicado: (2016)

Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma
por: Feng, Yiyi, et al.
Publicado: (2021)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

Janus Kinases in Leukemia
por: Raivola, Juuli, et al.
Publicado: (2021)

Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease
por: Siegmund, Britta
Publicado: (2020)

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
por: Huo, Rongxiu, et al.
Publicado: (2023)

Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient
por: Berbert Ferreira, Sineida, et al.
Publicado: (2021)

An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy
por: Fojnica, Adnan, et al.
Publicado: (2023)

Characterization of a Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Cell Line CVG-1
por: Velásquez, Celestino, et al.
Publicado: (2018)

Merkel Cell Polyomavirus and Merkel Cell Carcinoma
por: Pietropaolo, Valeria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tvm0npm0ko9n6t46ag8jhim9ks